person
Peter H.
- Country
- Germany
- Department
- Clinic for Internal Medicine II
Research Overview
assignment
12
Clinical Trials ·
- Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients with Moderate to Severe Ulcerative Colitis
- A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis
- Efficacy and Safety of Obefazimod (ABX464) in Adults with Moderately to Severely Active Ulcerative Colitis: A Randomized Placebo‑Controlled Phase III Study
location_city
2
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
211
Sites with multiple studies
Has run more than one trial at 211 of 432 partner sites.
Specializations
Inflammatory Bowel Disease Research
The investigator specializes in treating ulcerative colitis and Crohn's disease, with particular emphasis on moderate to severe manifestations of these conditions.
- Novel therapeutic approaches for ulcerative colitis
- Advanced treatment strategies for Crohn's disease
- Long-term disease management solutions
Gastrointestinal Disorders
Expertise extends to various gastrointestinal conditions, including celiac disease and gastroesophageal junction adenocarcinoma.
- Celiac disease symptom management
- Gastrointestinal oncology
- Digestive system disorders
Advanced Therapeutic Applications
The investigator works with innovative treatment approaches including microbiome-based therapies and targeted immunological treatments.
- Biological therapy development
- Microbiota transplantation
- Immunological interventions
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.